Novo Nordisk drags competitor to court over Saxenda copies

According to Novo Nordisk, a firm based in India has made a copy of its obesity drug, Saxenda. Novo is now fighting to get the copy off the market in a US court.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by marketwire, translated by catherine brett

Novo Nordisk has summoned Orbicular Pharmaceutical Technologies before a court in Delaware in the US to block the launch of a generic copy of its obesity drug, Saxenda, Bloomberg News reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading